Results 71 to 80 of about 26,368 (251)

Model‐Driven Optimization of Subcutaneous Polymer Prodrugs Achieves Cancer Remission in Mice

Advanced Healthcare Materials, EarlyView.
A pharmacokinetics/pharmacodynamics (PK/PD) model was developed to evaluate multiple dosing regimens for subcutaneously administered water‐soluble polymer prodrug for cancer therapy. The model enabled prediction of in vivo performance and contributed to the optimization of anticancer efficacy.
Anne Rodallec, Randy Lee, Jingming Cao, Sophie Marolleau, Julien Nicolas, Sébastien Benzekry   +5 more
wiley   +1 more source

Albumin-bound paclitaxel in solid tumors: clinical development and future directions

Drug Design, Development and Therapy, 2015
Madappa N Kundranda,1 Jiaxin Niu21Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, 2Department of Medical Oncology, Cancer Treatment Centers of America, Goodyear, Arizona, USA Abstract: Albumin-bound paclitaxel (nab-paclitaxel) is a solvent ...
Kundranda MN, Niu J
doaj  

Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

BMC Cancer, 2020
Background Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer. Although UC has been considered a highly aggressive malignancy, no clinical studies have addressed the efficacy of chemotherapy for unresectable UC ...
Hiroshi Imaoka, Masafumi Ikeda, Kosuke Maehara, Kumiko Umemoto, Masato Ozaka, Satoshi Kobayashi, Takeshi Terashima, Hiroto Inoue, Chihiro Sakaguchi, Kunihiro Tsuji, Kazuhiko Shioji, Keiya Okamura, Yasuyuki Kawamoto, Rei Suzuki, Hirofumi Shirakawa, Hiroaki Nagano, Makoto Ueno, Chigusa Morizane, Junji Furuse   +18 more
doaj   +1 more source

A five arm natural history study of nasal vestibulitis

Cancer Medicine, 2023
Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐taxane, non ...
Elizabeth J. Cathcart‐Rake, David Zahrieh, Deanne Smith, Susan Young, Shaylene McCue, Amanda O'Connor, Stephan Thomé, Mario Lacouture, Terra Register, Jill Piens, Bret B. Friday, Charles L. Loprinzi   +11 more
doaj   +1 more source

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer [PDF]

, 2017
Nab-paclitaxel (NPT) combination with gemcitabine (Gem) represents the standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Genetic alterations of the RAS/RAF/MEK/ERK (MAPK) signaling pathway yielding constitutive activation of the ERK ...
Awasthi, Niranjan, Monahan, Sheena, Schwarz, Margaret A., Schwarz, Roderich E., Stefaniak, Alexis   +4 more
core   +1 more source

Nab-paclitaxel/Gemcitabine Induced Acquired Ichthyosis

SKIN The Journal of Cutaneous Medicine, 2018
The ichthyoses are a diverse group of cutaneous disorders characterized by abnormalities in cornification. The majority of ichthyoses are inherited with childhood presentation and new onset ichthyosis in adulthood warrants further medical evaluation. Though most well recognized for its association with Hodgkin’s disease, acquired ichthyosis (AI) has ...
Adriana T Lopez, Joel Shugar, Mark Lebwohl   +2 more
openaire   +1 more source

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results [PDF]

JNCI: Journal of the National Cancer Institute, 2017
Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results in higher pCR rates with uncertain survival impact.
Oleg, Gluz, Ulrike, Nitz, Cornelia, Liedtke, Matthias, Christgen, Eva-Maria, Grischke, Helmut, Forstbauer, Michael, Braun, Mathias, Warm, John, Hackmann, Christoph, Uleer, Bahriye, Aktas, Claudia, Schumacher, Nikola, Bangemann, Christoph, Lindner, Sherko, Kuemmel, Michael, Clemens, Jochem, Potenberg, Peter, Staib, Andreas, Kohls, Raquel, von Schumann, Ronald, Kates, Ronald, Kates, Johannes, Schumacher, Rachel, Wuerstlein, Hans Heinrich, Kreipe, Nadia, Harbeck   +25 more
openaire   +3 more sources

Efficacy and Safety Assessment of 5‐Fluorouracil, Irinotecan and Oxaliplatin‐Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy

Advanced Materials, EarlyView.
A novel FIRINOX‐loaded implant demonstrates controlled drug release, and potent therapeutic efficacy in pancreatic ductal adenocarcinoma mouse models with safety confirmed in a large‐animal pre‐clinical model. This innovative drug delivery platform offers a promising new treatment approach for non‐resectable, treatment‐resistant pancreatic cancer ...
Samantha J. Wade, Ashna A. Kumar, Samuel O. Nitschke, Paul Joyce, Elahe Minaei, Stephanie E. Reuter, Chelsea Penney, Holly Warren, Ruby Shepherd, Jeremy N. Dinoro, Gordon G. Wallace, Anthony Dosseto, Sameera Ansar, Naila Islam, Alistair Lochhead, George Sharbeen, Phoebe A. Phillips, Morteza Aghmesheh, Wayne J. Hawthorne, Kara L. Vine‐Perrow   +19 more
wiley   +1 more source

Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis

Journal of International Medical Research, 2020
Objective This study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with conventional taxanes as neoadjuvant chemotherapy for breast cancer. Methods We searched the literature using PubMed, the Cochrane Library,
Yong Li, Xiaoju Lu, Qimou Lin, Weiwen Li
doaj   +1 more source

Chronic Hypoxia Disrupts Spermatogenesis Through ASXL2–EZH2–Mediated Microtubule Destabilization

Advanced Science, EarlyView.
This study reveals the mechanism by which chronic hypoxia impairs spermatogenesis via the ASXL2–EZH2 axis, hindering the transition of spermatids from round to elongated forms. Key findings reveal that under hypoxic conditions, downregulated ASXL2 expression reduces EZH2 binding to the CEP162 promoter, leading to decreased H3K27me3 modification and ...
Jun Yin, Mengjie Zhang, Wenying Liu, Wenlong Shen, Debao Li, Hongming Miao, Fang Deng, Gang Zhang, Yi Tian, Yi Zhang, Zhihu Zhao, Bing Ni   +11 more
wiley   +1 more source